slightli trim gilead fve follow hiv
updat forecast estim may
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research may
estim may
price data may
rate updat may
currenc amount express
valuat growth profit
methodolog valu compani
gilead gener stellar profit margin hiv hcv
portfolio requir small salesforc inexpens
manufactur think firm portfolio pipelin support
wide moat gilead need hcv market stabil strong
continu innov hiv solid pipelin data smart futur
acquisit return growth
gilead tenofovir molecul -- viread truvada older
single-tablet regimen -- histor form heart firm
afford less like miss dose develop
drug resist need make one co-payment older
combo pill atripla first replac gilead complera
stribild better safeti profil newest combo
pill -- replac tdf taf -- reduc bone kidney safeti
issu see rapid uptak gilead biggest competit
threat hiv glaxo triumeq saw rapid growth glaxo
 test novel combin also bypass gilead
biktarvi launch push patent protect
late boost market share
sovaldi harvoni combin sovaldi ledipasvir
peak billion sale howev demand
shrink patient cure competit
merck led sever round signific
price-discount expect gilead current
launch eight-week regimen mavyret share billion-plu
market long term
gilead build pipelin outsid hiv hcv need
acquisit like kite car-t therapi yescarta see
strong growth gilead first cancer drug zydelig launch
limit safeti concern optimist
galapago collabor lead nash program selonsertib
also phase open multi-billion-dollar opportun
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
develop market therapi treat life-threaten
infecti diseas core portfolio focus hiv
hepat acquisit coru pharma myogen cv
therapeut arresto bioscienc calistoga broaden focu
includ pulmonari cardiovascular diseas cancer gilead
acquisit pharmasset brought right hepat drug sovaldi
also part combin drug harvoni kite acquisit boost
gilead exposur cell therapi oncolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
slightli trim gilead fve follow
trim product sale assumpt year
hepat gilead see new competit
hiv/hbv hit viread gener
hbv steeper hiv inventori drawdown market
prepar convers firm latest single-tablet
regimen biktarvi weve slightli lower fair valu
estim per share result howev
share look slightli under-valued think market
undervalu gilead hiv portfolio well oncolog
portfolio immunology/nash pipelin support
firm wide moat expect key pipelin data
nash drug selonsertib immunolog drug filgotinib
ra first half
biktarvi sale million quarter
expect becom gilead largest hiv product
easili reach billion peak biktarvi
approv februari like gain approv
europ third quarter patient appear
switch gilead genvoya cannib gilead hiv
sale also glaxo tivicay triumeq
slightli expand market share roughli
gilead hiv sale volum taf-contain
regimen think bode well firm resili
face on-going gener pressur europ
anticip patent expir
yescarta sale million first quarter
maintain view sale could reach
billion billion peak howev
reimburs take time given inpati
set hospit gilead also ramp
number center author administ drug
novarti compet car-t cell therapi kymriah
approv fda dlbcl think gilead
retain first-mov advantag indic
gilead total product sale fell base
combin hiv/hbv growth signific
declin firm hcv portfolio hiv/hbv growth face
headwind lower inventori manag note
demand remain strong prescript growth
quarter hcv expect slightli
pressur addit quarter gain share
price appear stabil non-gaap oper
margin fell roughli percentag point
oper margin first quarter due slightli
lower gross margin attribut partli dramat
lower hcv price well higher sell gener
administr expens firm focus launch
new oncolog therapi yescarta hiv therapi biktarvi
valuat growth profit may
follow first-quart result lower
gilead fair valu estim per share
slightli trim hiv hcv sale
estim year
assum billion gilead hcv sale
almost lower patient demand key
headwind follow addit price headwind
next-gener product mavyret
result see gilead hcv revenu billion
assum averag net price around
overal think gilead hiv/hbv franchis peak
billion gener competit lead
roughli averag annual headwind begin
assum taf-bas combin
regimen biktarvi genvoya descovi odefsey
gilead could see
help off-set declin
 annual
begin still view stribild complera
gener strong long-term competit taf-bas
regimen particularli outsid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
still think firm warrant medium uncertainti
rate owe volatil hepat market demand
price
bullish scenario expect gilead achiev stronger
convers newer hiv product stronger
hepat price power scenario assum hiv
franchis sale peak billion follow
midteen declin face gener competit
also assum less aggress rebat hepat
 market bull-cas scenario result
billion hepat sale gilead also
use slightli higher earnings-growth rate stage ii
model result fair valu estim
per share
pessimist scenario assum complera
stribild next-gener taf-bas regimen like
genvoya biktarvi unabl gain signific share
hiv market lack perceiv efficaci
safeti conveni benefit compar older
regimen glaxo doublet regimen hiv franchis sale
peak billion fall averag
annual owe sever pressur scenario
assum addit price competit hepat
market result less billion hepat
sale gilead also use earnings-growth
rate stage ii model yield
patent protect newer hiv regimen gilead
continu domin hepat market
enough ensur strong return next coupl
decad gilead expertis infecti diseas
single-pil formul part research
develop strategi see one strongest
forecast averag annual sale non-gaap
earn declin sovaldi harvoni high
gross margin strong oper leverag lower tax rate
led oper margin shrink
revenu think margin declin
assum cost-cut help off-set margin
includ billion sale yescarta
eventu surpass billion usag expand
second-lin dlbcl therapi form blood cancer
assum cost capit gilead rate
systemat risk surround gilead share
averag assum cost equiti align
capit cost assumpt return equiti investor
like demand long run also assum
pre-tax cost debt reflect normal
gilead portfolio divers hiv focu
expand exposur hepat cancer market
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
intang asset support firm wide moat
gilead moat form leadership posit
treatment hiv three patent product form
backbon today treatment regimen despit
numer competitor compani establish
lead market share spectacular profit
conveni effect safe treatment gilead serv
treat hiv patient unit state
manag done excel job maxim sale
tdf molecul present viread truvada
atripla complera stribild said key patent
begin expir europ next-gener product
could struggl provid suffici differenti
reimburs key market put pressur
howev think firm shown translat
extens understand drug discoveri
develop process hiv new therapeut area
allow achiev wide-moat statu despit initi
critic high price gilead paid pharmasset
earli billion acquisit gave gilead
valuabl hepat drug industri also
demonstr firm abil recogn potenti
uniqu natur sovaldi safeti efficaci profil
compar toxic nucleotid analog think
firm experi anoth nucleotid analog tenofovir
key ingredi gilead hiv combin regimen
probabl contribut recognit sovaldi valu
earli stage develop
molecul sovaldi harvoni redefin gilead
powerhous broader infecti diseas market
gilead lead way all-or treatment
hepat market gilead multi-billion-dollar
product think low resist potenti
pan-genotyp efficaci gilead regimen allow
firm retain close global hcv market
long run despit competit merck
product platform reflect grow record recogn
potenti infecti diseas discoveri
foundat hiv drug tenofovir deal brought right
emtricitabin anoth ingredi gilead
combin regimen elvitegravir integras inhibitor
stribild sovaldi gilead oncolog pipelin also
grow advanc receiv boost
recent acquisit kite includ car-t cell therapi
yescarta think firm smart acquisit
potenti futur combin regimen hematolog
oncolog immunolog nash diversifi
firm strengthen intang asset howev
think gilead hiv-rel patent exposur price
volum headwind hepat market prevent
moat expand
see grow evid firm acquisit
strategi could serv well oncolog immunolog
follow sever year smaller acquisit
idelalisib via calistoga launch safeti risk
limit usag later line therapi howev
oncolog drug safer dose zydelig combin
therapi still test sever potenti
immunolog indic well yescarta acquir
kite pharma octob launch diffus
larg b-cell lymphoma think gilead histori
smart clinic trial design market expertis could
boost launch speed long-term potenti kite
portfolio addit acquisit arresto nimbu
apollo well licens deal phenex given
gilead sever differ mechan treat nash
potenti combin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
gilead product biolog firm
vulner gener version mani older hiv
product within five year howev newer hiv regimen
complera stribild saw strong launch genvoya
improv kidney bone safeti profil led fastest
hiv combin pill sale ramp help
differenti drug gener version gilead
truvada atripla stribild genvoya gilead
retain virtual econom behind hiv sale
rather share partner complera
johnson johnson atripla bristol-my squibb
benefit firm return invest capit
gilead also face strong competit hiv still see
gilead best-posit field approv
glaxo integras inhibitor tivicay combin tablet
triumeq epzicom/tivicay led gilead market share
declin glaxo gilead appear
gain share hiv player merck bristol
lack combin pill expect gilead
biktarvi launch glaxo juluca approv
anoth dual-combo pill phase test continu
domin market
gilead pipelin continu sale hiv beyond first
wave patent expir need counter declin
hcv tough year sale
declin bring larger hit demand
falter launch next-gener product
beyond assum annual headwind hcv
sale remain forecast period price patient
demand declin rel steadili beyond
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ogilead market sever single-tablet regimen hiv
firm next-gener product better
long-term safeti profil led genvoya biktarvi
boost gilead market share
ogilead hiv franchis see first import
patent expir firm
need convert patient newer product like
genvoya biktarvi avoid signific hit sale
oguidelin aim
improv diagnosi
treatment rate new prophylaxi use provid
strong tailwind growth hiv
owith approv sovaldi harvoni gilead
market leader all-or hepat treatment
none gilead competitor nucleotid
analog make billion acquisit
opric pressur reduc willing pay
conveni could weigh gilead growth atripla
becom formid gener competitor
gilead newer hiv product compet
hepat regimen give pbm abil
ohcv patient demand plummet visibl
long-term demand price low
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
gilead held billion cash billion debt
end gilead continu rais debt rel
low rate assum blend interest rate
includ billion debt term loan
support octob acquisit kite pharma gilead
use cash fund aggress share repurchas
billion rel new dividend gilead hiv
hcv busi also gener stellar cash flow
despit declin hcv sale gilead easili gener
around billion free cash flow annual
expect gilead use cash futur
acquisit particularli tax reform allow repatri
oversea cash note share repurchas
dial back significantli fund dividend growth
acquisit
increas competit price pressur hiv
hepat market risk gilead global price
pressur consolid pharmacy-benefit manag
could reduc gilead abil charg price premium
new drug extend patent protect gilead newest
hiv product perceiv offer improv safeti
efficaci versu older hiv product larg portion
sale foundat could risk patent gilead
top market hiv product expir firm
need see signific switch newer product like
genvoya counter neg impact gener
competitor estim gilead
purchas higher rebat sale
implement escal overal healthcar cost
tight budget could lead continu elev price
pressur europ gilead also paid
signific premium acquir myogen failur
darusentan put even pressur letairi make
deal accret said billion pharmasset
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
acquisit foundat gilead hcv franchis
allow gilead gener billion hcv
revenu howev gilead hcv busi declin
steepli competit allow pharmaci benefit
manag like express script aggress negoti
price gilead appear gain vast major
contract access patient sacrif price
safe effect
competit -- like gilead atripla complera -- lose
formulari
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
va collegeamerica invmt co america
fidel manag research compani
new york mellon corp
share
fund
share
fund
assign gilead exemplari mark stewardship base
moat-build invest strategi good alloc
capit superior board
independ
qualif gilead made sever acquisit
collabor deal year support
infecti diseas portfolio exampl acquisit
triangl brought emtriva critic compon
truvada firm single-tablet hiv regimen
outsid gilead therapeut area focu acquisit
cv also wise invest angina
drug ranexa grow strongli addit billion
bet pharmasset -- hepat drug sovaldi --
excel use capit earli judg
billion acquisit kite pharma current
assum deal neutral long-term roic upsid
possibl yescarta uptak faster expect
john martin step role ceo march
current serv chairman board
transit execut chairman chairman march
appreci martin still voic
gilead strategi given tenur ceo
background antivir chemistri bristol john milligan
promot ceo also join
board milligan martin insid gilead
board independ lead director
includ expertis public polici infecti diseas
global health initi like manag
reward progress rather earn per share
gilead decis boost share repurchas
smart one view share trade fair
valu estim much past three year see
blood cancer immunolog key area futur growth
gilead
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
slightli trim gilead fve follow
trim product sale assumpt year
hepat gilead see new competit
hiv/hbv hit viread gener
hbv steeper hiv inventori drawdown market
prepar convers firm latest single-tablet
regimen biktarvi weve slightli lower fair valu
estim per share result howev
share look slightli under-valued think market
undervalu gilead hiv portfolio well oncolog
portfolio immunology/nash pipelin support
firm wide moat expect key pipelin data
nash drug selonsertib immunolog drug filgotinib
ra first half
biktarvi sale million quarter
expect becom gilead largest hiv product
easili reach billion peak biktarvi
approv februari like gain approv
europ third quarter patient appear
switch gilead genvoya cannib gilead hiv
sale also glaxo tivicay triumeq
slightli expand market share roughli
gilead hiv sale volum taf-contain
regimen think bode well firm resili
face on-going gener pressur europ
anticip patent expir
yescarta sale million first quarter
maintain view sale could reach
billion billion peak howev
reimburs take time given inpati
set hospit gilead also ramp
number center author administ drug
novarti compet car-t cell therapi kymriah
approv fda dlbcl think gilead
retain first-mov advantag indic
gilead total product sale fell base
combin hiv/hbv growth signific
declin firm hcv portfolio hiv/hbv growth face
headwind lower inventori manag note
demand remain strong prescript growth
quarter hcv expect slightli
pressur addit quarter gain share
price appear stabil non-gaap oper
margin fell roughli percentag point
oper margin first quarter due slightli
lower gross margin attribut partli dramat
lower hcv price well higher sell gener
administr expens firm focus launch
new oncolog therapi yescarta hiv therapi biktarvi
gilead hcv headwind final surmount
maintain fair valu estim gilead
follow in-lin result forecast
match previou bottom-lin assumpt howev
plan significantli lower hepat sale forecast
match gilead guidanc discount
fourth quarter go steeper
expect also significantli lower tax rate
assumpt beyond due tax reform
gilead result reflect continu growth stori
billion hiv hepat portfolio growth
declin billion hcv portfolio
weigh top line saw declin overal
forc gilead tax rate higher result
declin non-gaap ep year overal think
gilead see steeper top-lin pressur
move sustain mid-single-digit top-lin growth
firm hiv portfolio look steadi
gilead hcv portfolio like declin
due competit think gilead nash
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ahead lead drug alreadi pivot studi
gilead therefor well behind lead player also
face potenti competit glaxo
see addit phase data gilead
nash pipelin expect meaning
catalyst phase data gilead lead drug
selonsertib gilead also expect begin larger phase
combin studi test variou two-drug
combin regimen dispos use selonsertib
inhibitor fxr agonist
addit billion cash repatri year
gilead abil supplement portfolio
expect hiv hcv sale continu diverg
hcv final begin stabil hiv gilead pois
gain food drug administr approv
bictegravir-bas combin pill next week
think help prevent hiv market share declin hcv
sale fell fourth quarter estim
price roughli per cure quarter slightli
list price mavyret
assum price level around per
cure gilead hcv sale -- pois shrink
roughli billion see subsequ high-
single-digit declin mostli due declin overal patient
demand hcv treatment
therapi lymphoma still support billion peak
sale estim yescarta think bcma
landscap competit assum gilead gain
signific share gilead saw million sale
new lymphoma car-t cell therapi yescarta
fourth quarter follow octob approv launch
expect slow requir signific physician
train administr involv reimburs
hurdl expect gilead well posit start
see signific ramp sale end
year see dlbcl opportun second-lin therapi
beyond billion market opportun
today think overal sale yescarta
indic also test form leukemia
lymphoma like reach billion long run
howev caution competit landscap cell
therapi evolv rapidli yescarta assumpt
could fall celgen pois launch
continu demonstr safeti edg addit
celgen sever bcma-target therapi move
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
